clinical trial · NCT06677138
PK Study of Gefurulimab SC in Healthy Chinese Adult Participants
Alexion Pharmaceuticals, Inc.·phase1·completed·n = 8
Healthygefurulimab
brief summary
The primary objective of this study is to characterize the PK properties of a single dose of gefurulimab in healthy Chinese participants.
started
Oct 28, 2024
primary completion
Mar 19, 2025
completion
Mar 19, 2025
last updated
May 1, 2025
official title
A Phase 1 Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Gefurulimab (ALXN1720) in Healthy Chinese Adults
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol